Audit: QRS - Lysine for Health & Longevity

Audit conducted on 13/09/2026 07:08 using AI4L / Opus 5

Iterations

Summary

Items	Count
Total	93
Passed	86
Failed	0
N/A	7
Pass Rate	100.00%

• Total = Passed + Failed + N/A
• Pass Rate = Passed / (Passed + Failed) × 100
• N/A items are excluded from the pass rate calculation

---

1. General Rules

#	Description	Result	Comments
1.1	Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER.	🟢	Protocol values, time-to-effect values, benefit/risk tier items, contraindications, interactions, all nine biomarkers and the cadence trace to ER lines 294–319, 341–371, 405, 435–454, 476–480.
1.2	Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing.	🟢	The ER’s “⚠️ Conflicted” flag on the cold-sore benefit is carried through as “, conflicted” (QRS line 550); “within a combination product” and “on lysine-limited diets” are retained.
1.3	The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”).	🟢	Absolute contraindications remain in the stop gate; conditional benefit qualifiers are retained rather than dropped.
1.4	The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc.	🟢	Stop and caution gates draw only from the ER Key Interactions & Contraindications section; Benefit- and Risk-Modifying Factors are not surfaced anywhere.
1.5	PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact.	🟢	No PMIDs, NCT identifiers, author names or brand names appear anywhere in the QRS.
1.6	The QRS does not introduce new attributions.	🟢	No attributions are present.

2. Focus, Tone & Audience

#	Description	Result	Comments
2.1	The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing.	🟢	Sober, evidence-weighted framing mirroring the ER Conclusion.
2.2	The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging	🟢	Numeric targets and doses are given alongside plain-language explanation.
2.3	The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor	🟢	Content is stated descriptively, not as instruction.
2.4	The QRS avoids language that implies medical or clinical advice	🟢	No imperatives or prescriptive verbs in the populated variables.
2.5	The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising”	🟢	Protocol cells state doses and forms; monitoring states markers and reasons.
2.6	The QRS never addresses “the reader” directly — it presents evidence, not guidance	🟢	No second-person pronouns anywhere in the document.
2.7	The QRS is written in plain language, avoiding unnecessary medical jargon	🟢	Technical terms carry ER glosses (e.g., “cholelithiasis (gallstones)”, “eGFR”).
2.8	Information is presented in a concise and very compact manner	🟢	All items are single clauses or semicolon-joined fragments.
2.9	It DOES NOT address the reader directly	🟢	Confirmed by scan for you/your/yourself.
2.10	The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review.	🟢	Framing assumes self-directed supplementation with biomarker tracking.
2.11	The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort.	🟢	Nine-marker laboratory panel and a multi-point cadence are presented without hedging on effort.
2.12	The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort.	🟢	Content depth (split dosing, salt-form arithmetic, tubular monitoring) is beyond general-population framing.
2.13	Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience.	🟢	The at-a-glance states that every supported effect was shown in lysine-short diets, which is the decisive distinction for a well-nourished reader.
2.14	The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim.	🟢	“Longevity” is used in the title and header; “anti-aging” does not appear.
2.15	The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “oral” / “administered orally” not “taken by mouth” / “given by mouth”; “injection” not “shot”; “adverse event” not “bad reaction”). This holds on EVERY surface, including the QRS lede — the stricter plain-language bar (see 2.7) does not license lay phrasing for route of administration. Direct quotes from sources are exempt.	🟢	“adverse effects”, “oral antiviral agents”, “gastrointestinal” are used; marker labels are ER verbatim.

3. Template Integrity

#	Description	Result	Comments
3.1	The following labels and headings on the QRS are fixed and not modified: Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”; Gate headings: “Contraindications”, “Key Interactions”; Tier labels: “High”, “Medium”, “Low”, “Speculative”; Table column headers in Monitoring: “Marker”, “Target”, “Why”	🟢	All headings, gate labels, tier labels and column headers match the template byte for byte.
3.2	All “…” from the [qrs_template] are present in the the QRS.	🟢	All 34 template variable names are present; marker_#* and qualitative_item# are expanded to 9 and 6 instances respectively.
3.3	Spans that are not addressed in a checklist item are left unchanged	🟢	website="evidence_review", website="audit" and website="full_review" spans are untouched; a structural diff against the template shows no other changes outside variable content.

4. Formatting

#	Description	Result	Comments
4.1	When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied”	N/A	No source ER section is empty; the empty Benefits-High tier is governed by item 12.5, which requires hiding rather than empty-state phrasing.
4.2	Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label.	🟢	“Standard supplemental dose”, “Single versus split dosing”, “Salt form and equivalence” are ER bold labels verbatim (ER lines 341, 359, 371).
4.3	Labels are not paraphrased, abbreviated, or invented.	🟢	Benefit/risk items reuse the ER’s H4 headings; marker names reuse the ER biomarker table’s first column.
4.4	The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels.	🟢	A Unicode scan returns no emoji; the ER’s ⚠️ and ⭕️ markers were not carried over.
4.5	The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page.	🟢	Every section is condensed relative to the ER: multi-sentence ER bullets become single clauses, magnitudes and context notes are dropped, and no section carries ER prose verbatim beyond its label.

---

5. Metadata

#	Description	Result	Comments
5.1	The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content.	🟢	Lines 2–14, immediately after the doctype on line 1.
5.2	Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML.	🟢	Opening “—” on line 3, closing “—” on line 13.
5.3	The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet.	🟢	Contained entirely within an HTML comment; no metadata value is repeated in the header or body.
5.4	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	Only duration: "00:03" is quoted, and it contains a colon.
5.5	The filename of the source ER is stated as “er_filename: [er_filename]”	🟢	Line 4: er_filename: lysine_2026-0913-0433_Opus_ER.md.
5.6	Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]”	🟢	Line 5: qrs_prompt_version: 26.9.11, matching this prompt’s version.
5.7	Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430)	🟢	Line 6: qrs_creation_date: 2026-0913-0659.
5.8	The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]”	🟢	Line 7: qrs_creator_ai_nickname: Opus.
5.9	The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT)	🟢	“Opus” is a single word without version.
5.10	The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]”	🟢	Line 8: qrs_creator_ai_fullname: Opus 5.
5.11	The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4)	🟢	“Opus 5” — nickname plus version, no qualifier.
5.12	The filename of the document is stated as “qrs_filename: [filename of this document]”	🟢	Line 9 matches the file’s own name on disk.
5.13	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	Re-verified across all nine keys; no stray whitespace or unnecessary quoting.

6. Page Title & Header

#	Description	Result	Comments
6.1	[page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &)	🟢	Line 22: “Lysine for Health & Longevity - Quick Reference Sheet”.
6.2	[header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &)	🟢	Line 417: “Lysine for Health & Longevity”.
6.3	[header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY]	🟢	Line 421: “09/13/2026”, matching qrs_creation_date 2026-0913.
6.4	[header_subline_model] is set to [qrs_creator_ai_fullname]	🟢	Line 425: “Opus 5”.
6.5	No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker.	🟢	Header contains only the title and the template subline; the ER’s “Also known as” line is not carried over.

7. At-A-Glance Section

#	Description	Result	Comments
7.1	[at_a_glance] is dense, execution-oriented summary of the ER Conclusion section	🟢	Condenses ER lines 476–480: safety ceiling, the deficiency precondition for benefit, and the contested cold-sore claim.
7.2	[at_a_glance] is no longer than 60 words	🟢	58 words.
7.3	Every fact in [at_a_glance] is supported by a distinct passage in the ER.	🟢	Nausea/diarrhoea and the six-gram ceiling from ER line 476; the deficiency precondition from line 478; the contested cold-sore claim from line 478.
7.4	It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead	🟢	No acronyms; “adverse effects” and “cold-sore” are the only clinical terms and both are in common use.
7.5	It DOES NOT cite specific trials (names, years, sample sizes, p-values)	🟢	No trial is named or dated.
7.6	It DOES NOT cite effect sizes, relative risks, or statistical results	🟢	Only the tolerability ceiling is numeric, and that is a dose, not a result.

8. Contraindications

#	Description	Result	Comments
8.1	The section is derived from the ER Key Interactions & Contraindications section	🟢	All eight items map to the ER’s “Populations who should avoid Lysine” list (ER lines 312–319).
8.2	[stop_items] represent the Contraindications from the ER	🟢	Eight ER entries, eight QRS items, in ER order with no additions or omissions.
8.3	Individual [stop_items] are formatted as <li></li>	🟢	Eight <li> elements inside the stop_items span (QRS lines 570–586).
8.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	The ER’s trailing clauses “— absolute contraindication; lysine restriction is the treatment”, “— absolute contraindication” and “where controlled safety data are absent” are all stripped.
8.5	Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	“stage 3 or worse (eGFR below 60 mL/min/1.73 m²)”, “(above 3.5 g per 24 hours)” and “(inherited blocks in lysine breakdown)” are retained.
8.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	🟢	The ER uses no ranking notation in this list; all parentheticals are already plain comma-separated text.
8.7	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no population, condition, or scenario for which the intervention should be avoided, deferred, or used only under specialist supervision.	🟢	The ER names eight such populations and the section is correspondingly populated.
8.8	If the section is left empty, an HTML comment inside the [stop_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g.	N/A	The section is not empty.

9. Key Interactions

#	Description	Result	Comments
9.1	The section is derived from the ER Key Interactions & Contraindications section	🟢	All eight items map to the ER’s interaction bullets (ER lines 294–308).
9.2	[caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications	🟢	Eight ER interaction bullets, eight QRS items, with no overlap against the eight contraindications.
9.3	Individual [caution_items] are formatted as <li></li>	🟢	Eight <li> elements inside the caution_items span (QRS lines 594–611).
9.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	The ER’s “Caution”/”Monitor” verdicts, mechanisms and “Mitigation:” sentences are all stripped; only the agent or class remains.
9.5	Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	Every ER example-drug list is retained; only the redundant “ibuprofen and other” is trimmed ahead of the class it belongs to.
9.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	🟢	The ER uses no ranking notation; all drug lists are plain comma-separated.
9.7	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no interaction, additive effect, or exposure that changes how the intervention is used.	🟢	The ER names eight interactions and the section is correspondingly populated.
9.8	If the section is left empty, an HTML comment inside the [caution_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g.	N/A	The section is not empty.

10. Protocol

#	Description	Result	Comments
10.1	The section is derived from the ER Protocol section	🟢	All three cells derive from ER Therapeutic Protocol lines 341, 359 and 371.
10.2	The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section	🟢	Dose range, dosing schedule and salt-form equivalence are the three decisions that determine how much lysine is actually delivered.
10.3	If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	The ER Therapeutic Protocol section contains seventeen bullets; all three sets are used.
10.4	All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section.	🟢	All nine variables carry substantive ER-derived content; no placeholders remain.

11. Time to Effect

#	Description	Result	Comments
11.1	The three sets of [time] items cover the three most important time-to-effect aspects from the ER	🟢	The ER’s Practical Considerations “Time to effect” bullet (line 405) names exactly three aspects and all three are carried over.
11.2	The sets are picked and ordered by the magnitude of the related benefit	🟢	Anxiety (Medium) and morbidity/strength (Medium) precede cold-sore frequency (Low), matching the ER’s benefit tiers.
11.3	If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	The ER supplies three distinct aspects; all three sets are used.
11.4	All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER.	🟢	“1–12 weeks”, “8–12 weeks” and “6 months” with ER-derived labels and sublines.
11.5	If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel	N/A	The ER does provide time-to-effect information.

12. Benefits

#	Description	Result	Comments
12.1	The section is derived from the ER Expected Benefits section	🟢	All ten items reuse the ER’s H4 benefit headings from lines 146–208.
12.2	Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative]	🟢	All four spans are present at QRS lines 540, 541, 548 and 555.
12.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	No Magnitude: figures, trial names or mechanisms are carried over; each item is a single ER heading.
12.4	Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	No parentheses appear in any benefits item.
12.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	🟢	The ER states no benefit reaches High (line 148); benefits_high is emptied and carries style="display: none" at line 540.

13. Risks

#	Description	Result	Comments
13.1	The section is derived from the ER Potential Risks & Side Effects section	🟢	All eight items reuse the ER’s H4 risk headings from lines 230–278.
13.2	Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative]	🟢	All four spans are present at QRS lines 623, 626, 631 and 637.
13.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	The pooled risk ratio, hazard ratios and the single case report are all omitted.
13.4	Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	No parentheses appear in any risks item; the ER’s glosses for Fanconi syndrome and tubulointerstitial nephritis are dropped.
13.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	N/A	All four risk tiers carry items in the ER, so no span needs hiding.

14. Monitoring

#	Description	Result	Comments
14.1	The section is derived from the ER Monitoring section	🟢	All rows derive from the ER Monitoring Protocol & Defining Success biomarker table (ER lines 435–445).
14.2	All measurable/quantifiable biomarkers from the Monitoring section are listed	🟢	All nine ER biomarkers are present with their optimal ranges and rationales intact.
14.3	[monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty.	🟢	QRS lines 793–795 reproduce the ER’s 4-week / 3-month / 6–12-month schedule from ER line 433.

15. Qualitative Assessment

#	Description	Result	Comments
15.1	The section is derived from the ER Monitoring section	🟢	All six items derive from the ER’s qualitative marker list (ER lines 449–454).
15.2	All subjective/qualitative biomarkers from the Monitoring section are listed	🟢	Six ER entries, six QRS items, none omitted.

Issues 13/09/2026 07:08

Pass rate 100.00%. No issues found.